NCT02273401View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

August 31, 2008

Conditions
Healthy
Interventions
DRUG

BI 11054 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY